Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Eur Urol Focus. 2018 Mar;4(2):219-227. doi: 10.1016/j.euf.2016.07.003. Epub 2016 Jul 29.
The main difference between the available magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion platforms for prostate biopsy is the method of image registration being either rigid or elastic. As elastic registration compensates for possible deformation caused by the introduction of an ultrasound probe for example, it is expected that it would perform better than rigid registration.
The aim of this meta-analysis is to compare rigid with elastic registration by calculating the detection odds ratio (OR) for both subgroups. The detection OR is defined as the ratio of the odds of detecting clinically significant prostate cancer (csPCa) by MRI-TRUS fusion biopsy compared with systematic TRUS biopsy. Secondary objectives were the OR for any PCa and the OR after pooling both registration techniques.
The electronic databases PubMed, Embase, and Cochrane were systematically searched for relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-analysis Statement. Studies comparing MRI-TRUS fusion and systematic TRUS-guided biopsies in the same patient were included. The quality assessment of included studies was performed using the Quality Assessment of Diagnostic Accuracy Studies version 2.
Eleven papers describing elastic and 10 describing rigid registration were included. Meta-analysis showed an OR of csPCa for elastic and rigid registration of 1.45 (95% confidence interval [CI]: 1.21-1.73, p<0.0001) and 1.40 (95% CI: 1.13-1.75, p=0.002), respectively. No significant difference was seen between the subgroups (p=0.83). Pooling subgroups resulted in an OR of 1.43 (95% CI: 1.25-1.63, p<0.00001).
No significant difference was identified between rigid and elastic registration for MRI-TRUS fusion-guided biopsy in the detection of csPCa; however, both techniques detected more csPCa than TRUS-guided biopsy alone.
We did not identify any significant differences in prostate cancer detection between two distinct magnetic resonance imaging-transrectal ultrasound fusion systems which vary in their method of compensating for prostate deformation.
目前可用于前列腺活检的磁共振成像-经直肠超声(MRI-TRUS)融合平台的主要区别在于图像配准的方法是刚性的还是弹性的。由于弹性配准可以补偿由于引入超声探头而导致的可能变形,因此预计它的性能会优于刚性配准。
本荟萃分析旨在通过计算两组的检测优势比(OR)来比较刚性和弹性配准。检测 OR 定义为 MRI-TRUS 融合活检检测临床显著前列腺癌(csPCa)的几率与系统 TRUS 活检的比值。次要目标是任何 PCa 的 OR 和两种配准技术合并后的 OR。
根据系统评价和荟萃分析报告的首选报告项目,系统地在 PubMed、Embase 和 Cochrane 电子数据库中搜索相关研究。纳入了在同一患者中比较 MRI-TRUS 融合和系统 TRUS 引导活检的研究。使用诊断准确性研究的质量评估 2 版对纳入研究进行质量评估。
描述弹性配准的 11 篇论文和描述刚性配准的 10 篇论文被纳入。荟萃分析显示,弹性和刚性配准的 csPCa 的 OR 分别为 1.45(95%置信区间 [CI]:1.21-1.73,p<0.0001)和 1.40(95% CI:1.13-1.75,p=0.002)。两组之间未见显著差异(p=0.83)。合并亚组得到的 OR 为 1.43(95% CI:1.25-1.63,p<0.00001)。
在 MRI-TRUS 融合引导活检中,刚性和弹性配准在检测 csPCa 方面没有发现显著差异;然而,这两种技术都比单独的 TRUS 引导活检检测到更多的 csPCa。
我们没有发现两种不同的磁共振成像-经直肠超声融合系统在前列腺变形补偿方法上存在差异,对前列腺癌检测有任何显著差异。